DUBLIN–(BUSINESS WIRE)–The “Global Dry Age-Related Macular Degeneration Clinical Trial Pipeline Highlights – 2022” report has been added to ResearchAndMarkets.com’s offering. This report provides the most up-to-date information on key pipeline produc…
Author: Business Wire
Global Optical Character Recognition Market Report to 2030 – Increasing Adoption of OCR Across Diversified Verticals is Driving Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optical Character Recognition Market Size, Share & Trends Analysis Report by Type (Software, Services), by Vertical (BFSI, Transport & Logistics), by End Use (B2B, B2C), by Region, and Segment Forecasts, 2022-2030″…
Guide Dogs for the Blind’s K9 Buddy Program Expands to Include the Entire United States and Adults of Any Age
SAN RAFAEL, Calif.–(BUSINESS WIRE)–Guide Dogs for the Blind (GDB) announced today that it has expanded the geographic and demographic scope if its K9 Buddy Program to include adults of any age who are blind or visually impaired throughout the U.S. GD…
The Worldwide Age-related Macular Degeneration Industry is Expected to Reach $14.4 Billion by 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Age-related Macular Degeneration Market Share, Size, Trends, Industry Analysis Report, By Drugs, By Product, By Route of Administration, By Distribution Channel, By Region, Segment Forecast, 2022 – 2030” report has been ad…
Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300
NASHVILLE, Tenn.–(BUSINESS WIRE)–Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced the dosing of the last patient in its Phase 2 pivotal efficacy and…
National Vision Holdings, Inc. Announces Third Quarter 2022 Earnings Release and Conference Call
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its third quarter 2022 financial results before the market opens on Thursday, November 10, 2022. The Company will host a confere…
Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022
PARSIPPANY, N.J.–(BUSINESS WIRE)–Iveric Bio announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022.
Lumata Health Raises $4 Million in Series A Funding to Scale its Human-Led, Intelligent Eye Care Management Platform
RALEIGH, N.C. & OKLAHOMA CITY–(BUSINESS WIRE)–Lumata Health raises $4MM in new venture funding to prevent blindness and address ophthalmology staffing challenges.
Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline results from two global Phase III studies, BALATON and COMINO, evaluating the first and only bispecific …
Rocky Mountain University Opens First College of Optometry in the Intermountain West
PROVO, Utah–(BUSINESS WIRE)– #highereducation–Rocky Mountain University receives preliminary accreditation for Doctor of Optometry program and will be the first in Utah and the Intermountain West.
Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22
Walmart Health Grows in Florida with 16 New Health Centers Opening in 2023
BENTONVILLE, Ark.–(BUSINESS WIRE)–Today, Walmart Health announced plans to bring more accessible, convenient, and affordable healthcare to communities in Florida with 16 new health centers. The locations will span the metro areas of Jacksonville, Orl…
Novaliq宣布FDA受理CyclASol®治疗干眼症的新药申请
德国海德堡和美国马萨诸塞州剑桥–(BUSINESS WIRE)–(美国商业资讯)–Novaliq是一家生物制药公司，专注于基于独家EyeSol®无水技术的同类首创一流眼科治疗药物。该公司今天宣布，美国食品药品管理局(FDA)已受理同类首创抗炎产品CyclASol®（环孢素滴眼液）用于治疗干眼症(DED)体征和症状的新药申请(NDA)。 FDA已完成CyclASol® NDA报批手续的审核，确定申请材料已充分齐全，可进入实质性审批阶段。目前尚未发现任何潜在的审核问题。FDA在审核该申请后设定的《…
ユーサウンドがTWS、補聴器、スマートメガネのバッテリー寿命を強化する高性能ASICリニアオーディオアンプを発表
オーストリア・グラーツ–(BUSINESS WIRE)–（ビジネスワイヤ） — MEMS技術ベースのヒアラブル・ウエアラブル向けオーディオソリューションを提供する主要企業のユーサウンドは、ユーサウンドMEMSスピーカー駆動用に設計した最新のASICリニアオーディオアンプ「Tarvos 1.0 UC-P3010」のリリースを発表します。 この革新的なASICリニアオーディオアンプは、ユーサウンドのMEMSスピーカーを最大40kHzの周波数帯域で駆動でき、最低ノイズ、最低高調波ひずみ、外部ノイズの…
USound发布高性能ASIC线性音频放大器，提高真无线立体声装置、助听器和智能眼镜的电池寿命
奥利地格拉茨–(BUSINESS WIRE)–(美国商业资讯)–USound是面向可听戴和可穿戴设备提供基于微机电系统(MEMS)技术的音频解决方案的领先供应商。该公司宣布推出最新的ASIC线性音频放大器Tarvos 1.0 UC-P3010，专用于驱动USound MEMS扬声器。 这款创新型ASIC线性音频放大器可在高达40kHz的频率范围内驱动USound MEMS扬声器，实现最低的噪音、最低的谐波失真和对外部噪音的高抑制。 ASIC线性音频放大器超越了市场要求，具有超低的功耗和高效率，…
USound发布高性能ASIC线性音频放大器，提高真无线立体声装置、助听器和智能眼镜的电池寿命
奥利地格拉茨–(BUSINESS WIRE)–(美国商业资讯)–USound是面向可听戴和可穿戴设备提供基于微机电系统(MEMS)技术的音频解决方案的领先供应商。该公司宣布推出最新的ASIC线性音频放大器Tarvos 1.0 UC-P3010，专用于驱动USound MEMS扬声器。 这款创新型ASIC线性音频放大器可在高达40kHz的频率范围内驱动USound MEMS扬声器，实现最低的噪音、最低的谐波失真和对外部噪音的高抑制。 ASIC线性音频放大器超越了市场要求，具有超低的功耗和高效率，…
Novaliq annonce l'acceptation par la FDA du dossier de demande de nouveau médicament pour CyclASol® pour le traitement de la sécheresse oculaire
HEIDELBERG, Allemagne, et CAMBRIDGE, Massachusetts, États-Unis–(BUSINESS WIRE)–Novaliq, une société biopharmaceutique qui se concentre sur des produits thérapeutiques oculaires pionniers et de la meilleure qualité basés sur la technologie exclusive E…
Novaliq annuncia che la FDA ha accettato la richiesta di nuovo farmaco per CyclASol® nel trattamento della sindrome dell'occhio secco
HEIDELBERG, Germania, e CAMBRIDGE, MA, USA–(BUSINESS WIRE)–Novaliq, una casa biofarmaceutica focalizzata su terapie oculari innovative e best in class basate sull’esclusiva tecnologia EyeSol® senz’acqua, oggi ha reso noto che la U.S. Food and Drug Ad…
Novaliq kondigt FDA-acceptatie aan van de nieuwe medicijnaanvraag voor CyclASol® voor de behandeling van droge-ogenziekte
HEIDELBERG, Duitsland & CAMBRIDGE, MA, USA–(BUSINESS WIRE)–Novaliq, een biofarmaceutisch bedrijf dat zich richt op eersteklas en best-in-class oculaire therapieën op basis van de unieke watervrije EyeSol®-technologie, heeft vandaag aangekondigd dat d…
Novaliq gibt FDA-Zulassung des Antrags für CyclASol® zur Behandlung der trockenen Augenkrankheit bekannt
HEIDELBERG, Deutschland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novaliq, ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung der ersten und besten Augentherapeutika auf Basis der einzigartigen wasserfreien EyeSol®-Technologie konzentriert, g…